RankingsPricing
  1. US-listed companies
  2. CATALYST PHARMACEUTICALS, INC.
  3. Financials
  4. Cash and cash equivalents

CATALYST PHARMACEUTICALS, INC.CPRX

Market cap
$2.9B
P/E ratio
SummaryFinancials
Period EndCash and cash equivalents (Million USD)YoY (%)
Dec 31, 2024518+276.03%
Dec 31, 2023138-53.87%
Dec 31, 2022298+74.05%
Dec 31, 2021171+31.64%
Dec 31, 2020130+45.50%
Dec 31, 201990+440.55%
Dec 31, 201817-71.20%
Dec 31, 201757+313.85%
Dec 31, 201614-50.79%
Dec 31, 201528+210.38%
Dec 31, 20149+310.51%
Dec 31, 20132+57.17%
Dec 31, 20121-76.61%
Dec 31, 20116

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)